Speech-Language Pathologists in La Feria, TX Accepting Medicare
3 Speech-Language Pathologists found. Showing 1 - 3
 Tiffany R Powell Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 505 N Villarreal St, La Feria, TX 78559 Phone: 956-797-8500 |
Saundra Deanna Ashley Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 313 Us-83 Bus., La Feria, TX 78559 Phone: 956-797-2100 Fax: 956-797-0000 |
 Jonathan Becerra, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 27282 Kelly Ct N, La Feria, TX 78559 Phone: 956-330-0015 |
News Archive
Pitt bioengineering student develops realistic phantom head for MR research
Phantoms are not just ghostly figures of our imagination, they are also numerical or physical models that represent human characteristics and provide an inexpensive way to test electromagnetic applications. Sossena Wood, a bioengineering PhD candidate at the University of Pittsburgh, has developed a realistic phantom head for magnetic resonance research in the Swanson School of Engineering.
Biomarker may signal whether common back pain treatment will work
A new study from researchers at the Stanford University School of Medicine has identified a unique protein complex that can be used to predict whether an epidural steroid injection will help relieve pain caused by a herniated disc in the lower spine.
Cleveland-based startup will use federal grant to develop AI tools for TB detection
Cleveland-Diascopic LLC, a Cleveland-based medical research company that develops diagnostic technology, will use a highly competitive federal grant to develop and apply new artificial intelligence and digital pathology tools for detecting tuberculosis.
Interim results from Phase 1 CAL-101 trial for chronic lymphocytic leukemia
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the presentation of interim results from the ongoing Phase 1 trial evaluating CAL-101, an oral delta-selective PI3K inhibitor, demonstrating promising clinical responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
Researcher uncovers secret life of Dab2 protein
Sometimes proteins do a lot more than we expect. Dab2, for example, has long been linked to cancer.
› Verified 8 days ago
Speech-Language Pathologists
Occupational Therapists
Physical Therapists